EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Potential interactions between medications for rate control and direct oral anticoagulants: Population-based cohort and case-crossover study

Angel Y S Wong, Charlotte Warren-Gash, Krishnan Bhaskaran, Clémence Leyrat, Amitava Banerjee, Liam Smeeth, Ian J Douglas

Heart Rhythm · 2024

DOI: 10.1016/j.hrthm.2024.06.033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Heart Rhythm, 2024. Verfasst von Angel Y S Wong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom. Electronic address: Angel.Wong…. Hauptthemen laut MEDLINE: Amiodarone, Cross-Over Studies, Drug Interactions. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, British Heart Foundation, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Direct oral anticoagulants (DOACs) are commonly co-prescribed with amiodarone/diltiazem/verapamil, but whether there is a drug interaction between these drugs is unclear. OBJECTIVE: The purpose of this study was to investigate the risk of clinical outcomes associated with concomitant use of DOACs and amiodarone/diltiazem/verapamil. METHODS: We identified DOAC users in the Clinical Practice Research Datalink Aurum from January 1, 2011, to December 31, 2019. We used a cohort design to estimate hazard ratios for ischemic stroke, myocardial infarction, venous thromboembolism, intracranial bleeding, gastrointestinal bleeding, other bleeding, cardiovascular mortality, and all-cause mortality, comparing DOACs + amiodarone/diltiazem/verapamil users and DOACs + beta-blocker users. A case-crossover design comparing odds of exposure to different drug initiation patterns for all outcomes in hazard window vs referent window within an individual also was conducted. RESULTS: Of 397,459 DOAC users, we included 9075 co-prescribed amiodarone, 9612 co-prescribed diltiazem, and 2907 co-prescribed verapamil. There was no difference in risk of any outcomes between DOACs + amiodarone/diltiazem/verapamil users vs DOACs + beta-blocker users in the cohort design. However, in the case-crossover design, we observed an odds ratio (OR) of 2.09 (99% confidence interval [CI] 1.37-3.18) for all-cause mortality associated with initiation of a DOAC while taking amiodarone, which was greater than that observed for DOAC monotherapy (OR 1.30; 99% CI 1.25-1.35). Similar findings were observed for cardiovascular mortality and all-cause mortality respectively with diltiazem. CONCLUSION: Our study showed no evidence of higher bleeding or cardiovascular risk associated with co-prescribed DOACs and amiodarone, diltiazem, or verapamil. Elevated risks of cardiovascular and all-cause mortality were only observed during DOAC initiation when diltiazem/amiodarone were being taken.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmiodaroneCross-Over StudiesDrug InteractionsAgedFemaleHumansMaleMiddle AgedAdministration, OralAnti-Arrhythmia AgentsAnticoagulantsAtrial FibrillationDiltiazemDrug Therapy, CombinationFactor Xa InhibitorsHeart RatePopulation SurveillanceRetrospective StudiesUnited StatesVerapamil

Stichwörter der Autor:innen

AmiodaroneDiltiazemDirect oral anticoagulantDrug–drug interactionsVerapamil

Substanzen

AmiodaroneAnti-Arrhythmia AgentsAnticoagulantsDiltiazemFactor Xa InhibitorsVerapamil

Autor:innen und Institutionen

  • Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom. Electronic address: Angel.Wong@lshtm.ac.uk.
  • Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Institute of Health Informatics, Faculty of Population Health Sciences, University College London UCL, London, United Kingdom.

Förderung

  • Medical Research Council
  • British Heart Foundation
  • Wellcome Trust
  • GlaxoSmithKline
  • Innovation and Technology Commission
  • UK Research and Innovation
  • Diabetes UK
  • British Council

Zitieren

APA

Wong, A. Y. S., Warren-Gash, C., Bhaskaran, K., Leyrat, C., Banerjee, A., Smeeth, L., & Douglas, I. J. (2024). Potential interactions between medications for rate control and direct oral anticoagulants: Population-based cohort and case-crossover study. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2024.06.033

Vancouver

Wong AYS, Warren-Gash C, Bhaskaran K, Leyrat C, Banerjee A, Smeeth L, et al. Potential interactions between medications for rate control and direct oral anticoagulants: Population-based cohort and case-crossover study. Heart Rhythm. 2024. doi:10.1016/j.hrthm.2024.06.033

BibTeX
@article{Wong2024,
  author = {Wong, Angel Y S and Warren-Gash, Charlotte and Bhaskaran, Krishnan and Leyrat, Clémence and Banerjee, Amitava and Smeeth, Liam and Douglas, Ian J},
  title = {Potential interactions between medications for rate control and direct oral anticoagulants: Population-based cohort and case-crossover study},
  journal = {Heart Rhythm},
  year = {2024},
  doi = {10.1016/j.hrthm.2024.06.033}
}
Kostenlos starten →